Elanco (ELAN) this morning announced that following feedback from the FDA, it expects the U.S. label of Zenrelia will include a boxed warning on safety based on the outcome of a trial with unvaccinated dogs dosed at three-times the label dose. Zenrelia is a treatment for canine atopic dermatitis, which will compete with Zoetis’ (ZTS) Apoquel. Shares of Zoetis are up 5% to $179.84 in morning trading while Elanco is down 15% to $15.22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS: